KORU Medical Systems filings document a Nasdaq-listed medical technology issuer focused on large-volume subcutaneous infusion products. The disclosures identify its common stock, operating results, earnings-release exhibits, non-GAAP measures such as adjusted EBITDA and adjusted diluted EPS, and the Freedom System product family used in home self-administration and ambulatory infusion settings.
Its SEC record also covers proxy governance, board and stockholder-meeting procedures, officer and compensation arrangements, and material agreements tied to the business. Recent 8-K filings describe credit-facility arrangements and manufacturing and supply agreements for subassemblies, needle sets, and tubing products.
KORU Medical Systems, Inc. reported second quarter 2026 net revenues of $12.0 million, up 18.2% from $10.2 million a year earlier, driven by 12.4% domestic core growth and 59.1% international core growth. Pharma services and clinical trials revenue declined 35.0% to $0.6 million.
Gross profit rose to $7.8 million with gross margin improving to 65.1%, while operating expenses increased 6.3% to $7.2 million. Net income was $0.25 million, or $0.01 per diluted share, compared with a net loss of $0.21 million. Adjusted EBITDA grew to $0.9 million, or $0.02 per adjusted diluted share.
Cash and cash equivalents were $8.3 million as of June 30, 2026, after $0.5 million of cash usage in the quarter. The company acquired a connected monitoring technology asset and entered a multi-year supply agreement. Full-year 2026 guidance now calls for net revenues of $47.5–$48.5 million, gross margin of 62–64%, positive adjusted EBITDA, and year-end cash above $7.5 million. KORU also withdrew its Phesgo® 510(k) and refocused its U.S. oncology strategy on higher-volume molecules.
BlackRock, Inc. reports beneficial ownership of common stock of KORU MEDICAL SYSTEMS INC. BlackRock and certain of its subsidiaries and affiliates collectively hold 2,575,761 shares of KORU common stock, representing 5.6% of the class.
BlackRock has sole voting power over 2,537,482 shares and sole dispositive power over 2,575,761 shares, with no shared voting or dispositive power reported. Various underlying clients and investors have rights to dividends or sale proceeds, but no single such person is reported to hold more than five percent of KORU’s outstanding common shares. The filing is signed by a BlackRock managing director.
KALBERMATTEN ADAM R reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems, Inc. reported that President and CEO Adam R. Kalbermatten received a grant of 284,091 Performance Stock Units tied to long-term performance goals. According to the award terms, 213,068 units may vest based on a target for the company’s net sales growth on or prior to 12/31/2030, and 71,023 units may vest based on achieving a specified market capitalization target as of 12/31/2030. The award represents a performance-based equity incentive linked to both operating and market outcomes.
KALBERMATTEN ADAM R reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems reported that President and CEO Adam R. Kalbermatten received a grant of 286,697 Performance Stock Units, each tied to an equal number of common shares. These awards were made under his amended and restated employment agreement as part of equity-based compensation.
According to the performance terms, 215,023 units may vest based on achieving a target level of the company's net sales growth on or prior to 12/31/2030, and 71,674 units may vest based on reaching a specified company market capitalization at 12/31/2030. All 286,697 units are reported as directly held following this grant.
KORU Medical Systems director Edward Wholihan received a grant of 3,571 shares of Common Stock, valued at $4.20 per share. This is a compensation-related award reported as an acquisition, not an open-market purchase. After the grant, his direct ownership totals 51,312 shares.
KORU Medical Systems director Matin Shahriar received a grant of common stock as part of equity compensation. On the reported date, Shahriar acquired 3,571 shares of KORU Medical Systems, Inc. common stock at $4.20 per share in a non-derivative award transaction.
Following this grant, Shahriar directly holds 101,144 shares of KORU Medical Systems common stock. This filing reflects a stock award rather than an open-market purchase or sale.
French Donna reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems director Donna French received a grant of 3,571 shares of Common Stock at $4.20 per share. This was a compensation-related award, not an open-market purchase. Following the grant, she directly holds a total of 98,514 KORU Medical Systems shares.
FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems director R. John Fletcher received a grant of 5,357 shares of Common Stock at $4.20 per share. This was a compensation-related award rather than an open-market purchase. After the grant, he directly owns 232,157 shares, indicating the award is a relatively small addition to his existing position.
CASCELLA ROBERT reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems director Robert Cascella received a grant of 3,571 shares of Common Stock at $4.20 per share as a compensation-related award. After this Form 4 transaction, he directly owns 98,155 shares of KORU Medical Systems common stock.